10 likes | 308 Views
Industry Adverse Event Subcommittee (*= SC member). Jackie Gough, ImClone Paul Mulhern, CBIIT, NCI Liviu Niculescu , M.D., Pfizer *Dianne Reeves, R.N., CBIIT, NCI Stephen Rubin, M.D., GlaxoSmithKline Mark Russo, M.D., GlaxoSmithKline Gwen Samuel, Bristol-Myers Squibb
E N D
Industry Adverse EventSubcommittee(*= SC member) • Jackie Gough, ImClone • Paul Mulhern, CBIIT, NCI • LiviuNiculescu, M.D., Pfizer • *Dianne Reeves, R.N., CBIIT, NCI • Stephen Rubin, M.D., GlaxoSmithKline • Mark Russo, M.D., GlaxoSmithKline • Gwen Samuel, Bristol-Myers Squibb • AlissaScalera, Ph.D.m,Pfizer • John Speakman, CBIIT, NCI • Ann Setser, R.N., CBIIT, NCI • Joyce Steinberg, MD, AstellasPharma • Simon Voss, ImClone • James A. Zwiebel, M.D., CTEP, NCI • Helen Chen, M.D, CTEP, NCI • Nathan Enas, MS Lilly • Diane Paul, Patient Advocate • Eileen Monge, BSN, RN Genentech • Anne Tompkins, RN, DCP, NCI • *Jeff Abrams, M.D., Cancer Therapy Evaluation Program (CTEP), NCI • Isaac Adegbile, ImClone • Deyaa Adib, Astellas Pharma • Cheryl Anderson, ImClone • *Rebecca Benner,Ph.D., Pfizer • Mark Benyunes, M.D., Genentech • Maria Bonura, Pfizer • Sophia Calmels, Ph.D., Pfizer • Jan Casadei, M.D., CTEP, NCI • Lorna Charles, M.D., Pfizer • Neesha Desai (Facilitator), Center for Biomedical Informatics and Information Technology (CBIIT), NCI • Robert Friedman, GlaxoSmithKline • Sherry Ansher, Ph.D, CTEP, NCI • John Freymann, CBIIT, NCI • Mark Steinberg, M.D., GlaxoSmithKline